Results 41 to 50 of about 281,748 (215)
Journal of Inflammation Research, 2023 Jing Yuan, Xuan Liu, Zhenzhen Wang, Liyuan Li, Fuxu Wang Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, People’s Republic of ChinaCorrespondence: Fuxu Wang, Department of Hematology, The Second ...
Yuan J, Liu X, Wang Z, Li L, Wang F
doaj
Is there a gender effect in polycythemia vera?
Annals of Hematology, 2020 In recent times, there has been a growing interest in understanding the impact of gender on disease biology and clinical outcomes in Philadelphia-negative chronic myeloproliferative neoplasms.
F. Palandri +3 more
semanticscholar +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2011 BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Leonardo Caires dos Santos +5 more
doaj +1 more source
Haematologica, 2012 Background Although reduction in the JAK2V617F allele burden (%V617F) has been suggested as a criterion for defining disease response to cytoreductive therapy in polycythemia vera, its value as a response monitor is unclear.
Emil Kuriakose +7 more
doaj +1 more source
Polycythemia vera as a presentation of renal angiomyolipoma: a case report
Journal of Medical Case Reports, 2009 Introduction Angiomyolipoma is a common benign renal tumor composed of thick-walled blood vessels, smooth muscle, and adipose tissue. It may be found incidentally during workup for suspected renal disease.
Lin Ming-Shyan +7 more
doaj +1 more source
The utility of testing erythropoietin level in polycythemia diagnosis
Hematology, 2023 Objectives: Polycythemia vera (PV) is classically thought to be associated with low erythropoietin (EPO) levels. Here, we present a review of the utility of using EPO levels in diagnosing polycythemia.Methods: We conducted a systematic literature review ...
Abdellatif Ismail +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT ...
Weizhe Jian +7 more
wiley +1 more source
Parathyroid Adenoma as a Rare Cause of Persistent Hypercalcemia in a Female with Polycythemia Vera
Case Reports in Oncology, 2020 Polycythemia vera is one of the myeloproliferative neoplasms that is distinguished by the uncontrolled production of blood cells and an increased red cell mass due to acquired JAK2 mutation.
Ahmed M. Abdalhadi, Mohamed A. Yassin
doaj +1 more source
American journal of hematology/oncology, 2018 Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding,
A. Tefferi, T. Barbui
semanticscholar +1 more source
From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
Haematologica, 2017 Polycythemia vera is a clonal disorder of hematopoietic stem/progenitor cells. It manifests as an expansion of red cell mass. It is the most common chronic myeloproliferative neoplasm. In virtually all cases, it is characterized by a V617F point mutation
Alessandro M. Vannucchi
doaj +1 more source